ACUR:OTC-Acura Pharmaceuticals Inc (USD)

COMMON STOCK | Drug Manufacturers-Specialty & Generic | OTC

Last Closing Price

USD 0.57

Change

0.00 (0.00)%

Market Cap

USD 0.04B

Volume

1.03K

Avg Analyst Target

N/A

Avg User Target

USD
Average Analyst Rating

N/A

Fundamental Analysis

Verdict

About

Acura Pharmaceuticals, Inc., an innovative drug delivery company, engages in the research, development, and commercialization of technologies and products to address safe use of medications in the United States. It offers Oxaydo tablets, a Schedule II narcotic indicated for the management of acute and chronic moderate to severe pain; and Nexafed products, which are pseudoephedrine and acetaminophen tablets that are used as nasal decongestants in various non-prescription and prescription cold, sinus, and allergy products. The company has six additional opioid products in various stages of formulation development. Acura Pharmaceuticals, Inc. has collaboration and license agreements with Egalet US, Inc.; and Egalet Ltd. to manufacture and commercialize Oxaydo products worldwide; and development and commercialization agreement with Abuse Deterrent Pharma, LLC to develop LTX-03, an immediate-release tablets utilizing LIMITx technology. The company was incorporated in 1935 and is based in Palatine, Illinois.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-09-18 )

Largest Industry Peers for Drug Manufacturers-Specialty & Generic

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MKKGY MERCK Kommanditgesellschaft au..

N/A

USD100.34B 31.09 19.81
MKGAF MERCK Kommanditgesellschaft au..

N/A

USD99.95B 31.01 19.81
TKPHF Takeda Pharmaceutical Company ..

N/A

USD54.34B 13.68 0.08
ESALF Eisai Co. Ltd

N/A

USD23.79B 43.50 0.18
ESALY Eisai Co. Ltd

N/A

USD22.26B 40.69 0.18
SFOSF Shanghai Fosun Pharmaceutical ..

N/A

USD21.71B 22.16 2.72
SGIOF Shionogi & Co. Ltd

N/A

USD20.65B 18.71 0.11
SGIOY Shionogi & Co. Ltd

N/A

USD20.51B 18.58 0.11
MTZPY Mitsubishi Tanabe Pharma Corpo..

N/A

USD10.43B 79.00 0.21
TEVJF Teva Pharmaceutical Industries..

N/A

USD10.28B 900.00 16.02

ETFs Containing ACUR

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers-Specialty & Generic)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 169.05% 90% A- 89% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 169.05% 89% B+ 89% B+
Trailing 12 Months  
Capital Gain 135.22% 80% B- 83% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 135.22% 80% B- 82% B-
Trailing 5 Years  
Capital Gain -64.24% 29% F 19% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -64.24% 29% F 19% F
Average Annual (5 Year Horizon)  
Capital Gain 3.03% 40% F 33% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 3.03% 39% F 30% F
Risk Return Profile  
Volatility (Standard Deviation) 62.32% 62% D- 43% F
Risk Adjusted Return 4.87% 39% F 26% F
Market Capitalization 0.04B 64% D 44% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers-Specialty & Generic)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 7.00 61% D- 74% C
Price/Book Ratio 93.19 6% F 3% F
Price / Cash Flow Ratio -53.11 89% B+ 91% A-
EV/EBITDA 15.70 24% F 23% F
Management Effectiveness  
Return on Equity N/A N/A N/A N/A N/A
Return on Invested Capital -92.61% 16% F 8% F
Return on Assets -13.37% 54% F 28% F
Debt to Equity Ratio -1.78% 75% C 84% B
Technical Ratios  
Short Ratio 0.73 50% F 54% F
Short Percent 0.95% 18% F 39% F
Beta 0.66 61% D- 60% D-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector